Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Non-Regulatory

Investor News Oncology Venture A/S to Provide Investor Updates at Upcoming Events in Q2 2020

Regulatory

Press release Oncology Venture receives feedback from U.S. FDA on potential approval pathway for Dovitinib.

Regulatory

Press release Oncology Venture to present on its DRP® technology at upcoming Google Cloud NEXT Conference.

Regulatory

Press release Oncology Venture & Alpha Blue Ocean mutually terminates agreement with EHGO as part of final financing

Regulatory

Press release Oncology Venture – First day of trading in TO2 warrants

Regulatory

Press release Oncology Venture to present a poster at upcoming PARP & DDR Inhibitor Summit on clinical development of 2X-121

Non-Regulatory

Press release Oncology Venture issues 287,500 new shares in connection with a debt conversion

Non-Regulatory

Press release Oncology Venture – Registration of current rights issue

Regulatory

Press release Swedish financier Mats Gabrielsson becomes major shareholder in Oncology Venture

Regulatory

Press release Oncology Venture rights issue fully subscribed

Regulatory

Company Announcement Oncology Venture publishes Interim Report for the period January – September 2019

Regulatory

Oncology Venture advancing towards next milestone in its clinical development of IXEMPRA®.

Regulatory

Oncology Venture is streamlining its communications by publishing press releases in English only going forward.

Non-Regulatory

Correction- Oncology Venture is streamlining its communications by publishing press releases in English only going forward.

Regulatory

Oncology Venture advancing towards next milestone in its clinical development of 2X-121.

Regulatory

Oncology Venture extends the subscription period of the current rights issue

Regulatory

Oncology Venture can inform that the last trading day of the Subscription Rights is now 19 November 2019, following the extension of subscription period until the 21 November of the current rights issue

Regulatory

Oncology Venture extends the subscription period of the current rights issue

Regulatory

Oncology Venture advancing towards next milestone in its clinical development of 2X-121.

Regulatory

Oncology Venture reaches new development milestone with Dovitinib.